Published in J Med Chem on April 08, 2010
Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci (2010) 3.61
Sequence determinants of a specific inactive protein kinase conformation. Chem Biol (2013) 1.78
Global kinomic and phospho-proteomic analyses of the human malaria parasite Plasmodium falciparum. Nat Commun (2011) 1.77
Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? ACS Chem Biol (2014) 1.23
Discovery of a potential allosteric ligand binding site in CDK2. ACS Chem Biol (2011) 1.15
Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors. Mol Pharmacol (2011) 1.14
FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas. J Biol Chem (2013) 1.09
Ten things you should know about protein kinases: IUPHAR Review 14. Br J Pharmacol (2015) 1.06
Chemical genetic strategy for targeting protein kinases based on covalent complementarity. Proc Natl Acad Sci U S A (2011) 1.01
Structure-kinetic relationship study of CDK8/CycC specific compounds. Proc Natl Acad Sci U S A (2013) 0.98
Kinome-wide activity modeling from diverse public high-quality data sets. J Chem Inf Model (2013) 0.98
Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. ACS Med Chem Lett (2014) 0.97
Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterization. J Med Chem (2010) 0.97
Enhanced ranking of PknB Inhibitors using data fusion methods. J Cheminform (2013) 0.95
Membranes serve as allosteric activators of phospholipase A2, enabling it to extract, bind, and hydrolyze phospholipid substrates. Proc Natl Acad Sci U S A (2015) 0.93
Structural determinants of PERK inhibitor potency and selectivity. Chem Biol Drug Des (2010) 0.88
A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis. Br J Pharmacol (2012) 0.86
Prospects for circumventing aminoglycoside kinase mediated antibiotic resistance. Front Cell Infect Microbiol (2013) 0.85
Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies. Expert Opin Drug Discov (2013) 0.84
Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-a]-Pyrazine Core. ACS Med Chem Lett (2010) 0.84
Small molecules dorsomorphin and LDN-193189 inhibit myostatin/GDF8 signaling and promote functional myoblast differentiation. J Biol Chem (2014) 0.84
Diaminopyridine-based potent and selective mps1 kinase inhibitors binding to an unusual flipped-Peptide conformation. ACS Med Chem Lett (2012) 0.82
Synthesis of a 6-methyl-7-deaza analogue of adenosine that potently inhibits replication of polio and dengue viruses. J Med Chem (2010) 0.82
Affinity-based probes based on type II kinase inhibitors. J Am Chem Soc (2012) 0.82
Discoidin domain receptor 1 (DDR1) kinase as target for structure-based drug discovery. Drug Discov Today (2014) 0.81
Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy. ACS Chem Biol (2015) 0.81
The human kinome and kinase inhibition. Curr Protoc Pharmacol (2013) 0.80
Structural basis for specificity of TGFβ family receptor small molecule inhibitors. Cell Signal (2011) 0.80
Are phylogenetic trees suitable for chemogenomics analyses of bioactivity data sets: the importance of shared active compounds and choosing a suitable data embedding method, as exemplified on Kinases. J Cheminform (2013) 0.79
Discovery of biarylaminoquinazolines as novel tubulin polymerization inhibitors. J Med Chem (2014) 0.79
Computational study of EGFR inhibition: molecular dynamics studies on the active and inactive protein conformations. J Mol Model (2012) 0.79
Discovery of a novel chemotype of tyrosine kinase inhibitors by fragment-based docking and molecular dynamics. ACS Med Chem Lett (2012) 0.79
Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization. Org Biomol Chem (2012) 0.78
Computational Modeling of Kinase Inhibitor Selectivity. ACS Med Chem Lett (2010) 0.78
Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach. Bioorg Med Chem Lett (2013) 0.78
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight (2016) 0.78
Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase. Nat Commun (2015) 0.78
The structure of human tau-tubulin kinase 1 both in the apo form and in complex with an inhibitor. Acta Crystallogr F Struct Biol Commun (2014) 0.77
Evaluating the predictivity of virtual screening for ABL kinase inhibitors to hinder drug resistance. Chem Biol Drug Des (2013) 0.77
c-Src binds to the cancer drug Ruxolitinib with an active conformation. PLoS One (2014) 0.77
Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Onco Targets Ther (2013) 0.77
(R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors. ACS Med Chem Lett (2015) 0.76
Can structural features of kinase receptors provide clues on selectivity and inhibition? A molecular modeling study. J Mol Graph Model (2015) 0.76
Clinical potential of pacritinib in the treatment of myelofibrosis. Ther Adv Hematol (2015) 0.75
Unprecedently Large-Scale Kinase Inhibitor Set Enabling the Accurate Prediction of Compound-Kinase Activities: A Way toward Selective Promiscuity by Design? J Chem Inf Model (2016) 0.75
A new tool for the chemical genetic investigation of the Plasmodium falciparum Pfnek-2 NIMA-related kinase. Malar J (2016) 0.75
Evaluation of 6-chloro-N-[3,4-disubstituted-1,3-thiazol-2(3H)-ylidene]-1,3-benzothiazol-2-amine Using Drug Design Concept for Their Targeted Activity Against Colon Cancer Cell Lines HCT-116, HCT15, and HT29. Med Sci Monit (2017) 0.75
The rational design of specific peptide inhibitor against p38α MAPK at allosteric-site: a therapeutic modality for HNSCC. PLoS One (2014) 0.75
A computational protocol to evaluate the effects of protein mutants in the kinase gatekeeper position on the binding of ATP substrate analogues. BMC Res Notes (2017) 0.75
Molecular Dynamics Simulations and Classical Multidimensional Scaling Unveil New Metastable States in the Conformational Landscape of CDK2. PLoS One (2016) 0.75
EGFR tyrosine kinase targeted compounds: in vitro antitumor activity and molecular modeling studies of new benzothiazole and pyrimido[2,1-b]benzothiazole derivatives. EXCLI J (2014) 0.75
Discovery of a series of novel phenylpiperazine derivatives as EGFR TK inhibitors. Sci Rep (2015) 0.75
Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases. ACS Med Chem Lett (2014) 0.75
Application of shape-based and pharmacophore-based in silico screens for identification of Type II protein kinase inhibitors. J Comput Aided Mol Des (2011) 0.75
Extended-spectrum antiprotozoal bumped kinase inhibitors: A review. Exp Parasitol (2017) 0.75
Allosteric Communication Networks in Proteins Revealed through Pocket Crosstalk Analysis. ACS Cent Sci (2017) 0.75
Molecular modeling study of the induced-fit effect on kinase inhibition: the case of fibroblast growth factor receptor 3 (FGFR3). J Comput Aided Mol Des (2015) 0.75
Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry (2010) 1.94
Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat Chem Biol (2013) 1.65
Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res (2007) 1.42
Alkylsulfanyl-1,2,4-triazoles, a new class of allosteric valosine containing protein inhibitors. Synthesis and structure-activity relationships. J Med Chem (2013) 1.02
A general NMR method for rapid, efficient, and reliable biochemical screening. J Am Chem Soc (2003) 0.94
RET inhibition: implications in cancer therapy. Expert Opin Ther Targets (2013) 0.90
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding. J Med Chem (2004) 0.86
PARP inhibitors in cancer therapy: an update. Expert Opin Ther Pat (2013) 0.86
Synthesis and SAR of new pyrazolo[4,3-h]quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors. Bioorg Med Chem Lett (2011) 0.85
p53-dependent downregulation of metastasis-associated laminin receptor. Oncogene (2002) 0.84
Reliable high-throughput functional screening with 3-FABS. Drug Discov Today (2004) 0.83
Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing. Bioorg Med Chem (2010) 0.81
NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases. Clin Cancer Res (2013) 0.81
Structural insight into maternal embryonic leucine zipper kinase (MELK) conformation and inhibition toward structure-based drug design. Biochemistry (2013) 0.80
Structure-based optimization of potent PDK1 inhibitors. Bioorg Med Chem Lett (2010) 0.80
Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors. J Mol Graph Model (2005) 0.78
Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases. Bioorg Med Chem (2013) 0.77
Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors. J Med Chem (2010) 0.77
Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90). Bioorg Med Chem (2013) 0.77
Synthesis of functionally diverse and conformationally constrained polycyclic analogues of proline and prolinol. J Org Chem (2003) 0.75
IP issues facing researchers by Gino D'Oca. Pharm Pat Anal (2012) 0.75
Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect. ChemMedChem (2014) 0.75
Conformationally stable and constrained macrocarbocyclic pseudopeptide mimics of beta-hairpin structures. Chemistry (2002) 0.75